National Academies of Sciences, Engineering, and Medicine: The Health Effects of Cannabis and Cannabinoids: Current State of Evidence and Recommendations for Research. Washington, DC: The National Academies Press, 2017.
5.
StrouseTB: Cannabinoids in medical practice. Cannabis Cannabinoid Res, 2016; 1:38–43.
6.
LembergerL, RubinA, WolenR, et al.: Pharmacokinetics, metabolism, and drug-abuse potential of nabilone. Can Treat Rev, 1982; 9(Suppl B):17–23.
7.
WhitingPF, WolffRF, DeshpandeS, et al.: Cannabinoids for medical use: A systematic review and metaanalysis. JAMA, 2015; 313:2456–2473.
8.
KoppelBS, BrustJC, FifreT, et al.: Systematic review: Efficacy and safety of medical marijuana in selected neurologic disorders: Report of the Guideline Development SubCommittee of the American Academy of Neurology. Neurology, 2014; 82:1556–1563.
9.
DevinskyO, MarshE, et al.: Cannabidiol in patients with treatment-resistant epilepsy: An open-label interventional trial. Lancet Neurol, 2016; 15:270–278.
10.
CichweiczDL, McCarthyEA: Antinociceptive synergy between delta-9THC and opioids after oral administration. J Pharmacol Exp Therap, 2003; 304:1010–1014.
11.
HurdYL: Cannabidiol: Swinging the marijuana pendulum from ‘weed’ to medication to treat the opioid epidemic. Trends Neurosci, 2017; 40:124–127.
12.
LynchME, Cesar-RittenbergP, HohmannAF: A double-blind, placebo-controlled crossover pilot trial with extension using an oral mucosal cannabinoid extract for treaemtne of chemotherapy-induced neuropathich pain. J Pain Sympt Manag, 2014; 47:166–172.
13.
NaftaliT, SchleiderLBL, DodtanI, et al.: Cannabis induces a clinical response in patient with Crohn's disease: A prospective placebo-controlled study. Clin Gastroen Hep, 2013; 11:1276–1280.
14.
NaftaliT, MechulamR, MariiA, et al.: Low-dose cannabidiol is safe but not effective in the treatment for Crohn's disease, a randomized controlled trial. Dig Dis Sci, 2017; 62:1–6.
15.
BelendiukKA, BaldiniLL, Bonn-MillerMO: Narrative review of the safety and efficacy of marijuana for the treatment of commonly state-approved medical and psychiatric disorders. Addict Sci Clin Pract, 2015; 10:10.
16.
VolkowND, BalerRD, ComptonWM, et al.: Adverse health effecst of marijuana use. NEJM, 2014; 370:2219–2227.
17.
MeierMH, CaspiA, CerdáM, et al.: Associations between cannabis use and physical health problems in early midlife: A longitudinal comparison of persistent cannabis vs tobacco users. JAMA Psych, 2016; 73:731–740.
18.
BachhuberMA, SalonerB, CunninghamCO, et al.: Medical cannabis laws and opioid overdose mortality in the United States 1999–2010. JAMA Intern Med, 2014; 174:1668–1673.
19.
Salomunson-SautelS, MinSJ, SakaiJT, et al.: Trends in fatal motor vehicle crashes before and after marijuana commercialization in Colorado. Drug Alcohol Depend, 2014; 140:137–144.
20.
BradAC, BradfordWD: Medical marijuana laws reduce prescription medication use in medicare part D. Health Affairs, 2016; 35:1230–1236.
21.
VandreyR, RaberJC, RaberME, et al.: Cannabinoid dose and label accuracy in medical cannabis products. JAMA, 2015; 313:2491–2493.
